Upload File

独立行政法人 医薬品医療機器総合機構...prior vegfr-tki=i prior vegfr-tk1>2 mskcc...

  • Home
  • Documents
  • 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
46

Upload: others

Post on 07-Mar-2021

4 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 2: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 3: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 4: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 5: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 6: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 7: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 8: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 9: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 10: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 11: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 12: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 13: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 14: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 15: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 16: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 17: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 18: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 19: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 20: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 21: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 22: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 23: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 24: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 25: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 26: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 27: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 28: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 29: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 30: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 31: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 32: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 33: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 34: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 35: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 36: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 37: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 38: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 39: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 40: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 41: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 42: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 43: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 44: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 45: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,
Page 46: 独立行政法人 医薬品医療機器総合機構...Prior VEGFR-TKI=I Prior VEGFR-TK1>2 MSKCC risk factors-=0 (favorable)C PITT population Cabozantinib N=330 61.7 (9.51) 62.5 (32,

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced ... · VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer Magali Terme1,

Development/Plasticity/Repair VEGFR ... · PDF fileDevelopment/Plasticity/Repair VEGFR-1RegulatesAdultOlfactoryBulbNeurogenesisand MigrationofNeuralProgenitorsintheRostralMigratory

Research Article 3D-QSAR Study on a Series of VEGFR-2

Role of targeted therapy in metastatic colorectal cancer · the VEGF family bind to three variants of receptors, VEGFR-1 (FLT-1), VEGFR-2 (FLK-1/KDR), and VEGFR-3 (FLT-4)[24,25]

Mechanisms and Management of Diarrhoea from Anti-VEGFR-TKIs · Mechanisms and Management of Diarrhoea from Anti-VEGFR-TKIs Manuela Schmidinger Medical University of Vienna Austria

Development/Plasticity/Repair VEGFR

Presentación de PowerPoint - seom.org · Vatalanib (PTK/ZK) TKI VEGFR-1, 2 Novartis/Schering AEE788 TKI VEGFR-2, EGFR Novartis ZD6474 TKI VEGFR-1, 2, 3, EGFR AstraZeneca

延边中医医院延吉市中医医院yanbian.wsglw.net/FilePool/AttachFile/News_ab38cd2c-022f... · Web viewEmail: yjzyyy @126.com 延边中医医院延吉市中医医院 二〇一五年十月三十日

Anti-angiogenic effects of ethanolic extract of Artemisia sieberi … · 2016. 6. 14. · artemisinin reduced the transcription of VEGFR-1, VEGFR-2 and CD34 genes in a concentration-dependent

ABCD - 医薬品医療機器総合機構...This document may not -in full or in part -be passed on, reproduced, published or otherwise used without prior written permission Nippon

PlGF/VEGFR-1 signaling promotes macrophage polarization and

New Trends In Internal Medicine2009 - Prince of Songkla ...medinfo2.psu.ac.th/.../Abstract/New_Trends_In_Internal_Medicine2009.pdf · Sorafenib multikinase inhibitor Raf, VEGFR PDGPR

INFORMAZIONI - Ospedali riuniti di Trieste · crescita anomala di vasi ed aumentata permeabilità vascolare come ... VEGFR-1 e VEGFR-2 ed impedendo la proliferazione delle cellule

Clinical Cancer Genotyping - CINVESTAVlabsergen.langebio.cinvestav.mx/bioinformatics/jacob/... · 2017. 10. 25. · EXEL-7647 EGFR, HER2, EphB4, VEGFR Inhibitor 2 EXEL-2880 MET, VEGFR-2

VEGF-B inhibits apoptosis via VEGFR-1– mediated

Cholesterol Regulates VEGFR-1 (FLT-1) Expression …...Signaling and Regulation Cholesterol Regulates VEGFR-1 (FLT-1) Expression and Signaling in Acute Leukemia Cells Cristina Casalou1,2,3,

Classification des anti-angiogéniques suivant leur …...IMC-2C6 InClone ACM VEGFR-2 GW-786034 GSK ITK VEGFR-1, 2, 3 Molécule Laboratoire Classe Cibles Les agents multi-cibles VEGFR-2

Mechanisms and Management of Diarrhoea from Anti-VEGFR-TKIs

Rational Approaches for Combination Therapy …...Regorafenib (BAY 73-4506) VEGFR-2 and -3, RET, KIT, PDGFR, RAF kinases 11167602 RTK/GFRs Pathways Cabozantinib (XL184) RET, MET, VEGFR-1,

1. 2. not · BC368, Exam 1, Spring 2014 2 6. VEGFR, a receptor tyrosine kinase, is required for the formation of new blood vessels. Activity of VEGFR-mediated signaling is often high

VEGFR-2 and VEGFR-3 Expression as a Function of Jagged-1 Over-Expression in HUVEC Cells Caleb Stubbs Mentor: Dr. Thomas Vandergon Pepperdine University

Report on the Deliberation Results · It was developed by ImClone Systems Incorporated. Ramucirumab binds to VEGFR-2 to block the binding of VEGF to VEGFR-2, thereby inhibiting the

VEGFR - file.medchemexpress.com

独立行政法人 医薬品医療機器総合機構...3.4 [1.4, 8. me114 k (3 n l) in vitr, GFRJ) (E rPDG VEGFR3 VEGFR2 VEGFR I RET FGFR2 KIT FGFR3 FGFRI F GFR3 K650E (nmol/l.) 2.33

HE Printed in U.S.A. Analysis of Biological Effects and ... · Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2) A REASSESSMENT USING NOVEL

Anti Vegfr y Anti Egfr

Meta-Analysis Efficacy and safety of targeting VEGFR drugs ...€¦ · receptor tyrosine kinases (VEGFR-1, -2, and -3). Of the VEGF receptors, VEGFR-2 expression is restricted to

in Wet AMD · 2014-09-11 · 1 3 6 7 4 ANGIOGENESIS VASCULOGENESIS VEGF-C VEGF-D VEGF VEGFR-3 (Flt-4) VEGFR-1 (Flt-1) VEGFR-2 (Flk-1) VEGF-A VEGF-B PIGF 1,2 Ras Raf MEK p38MAPK ERK

Soluble VEGFR-2 Expression in Head and Neck Malignant Tumors

ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows ... · Small Molecule Therapeutics ODM-203, a Selective Inhibitor of FGFR and VEGFR, Shows Strong Antitumor Activity, and Induces

Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth ...Targeting FGFR/PDGFR/VEGFR Impairs Tumor Growth, Angiogenesis, and Metastasis by Effects on Tumor Cells, Endothelial Cells, and Pericytes

Identification of potent VEGFR-2 Inhibitors of ... · Identification of potent VEGFR-2 Inhibitors of Angiogenesis through homology modeling, structure based virtual screening, docking

中医学医学硕士 奖学金 · 2019-04-10 · 针灸及经络学 中药及方剂 中医临床医学 生物医学 西医临床医学 中西医临床医学 痛症治疗学 中医保健(太极，气功,

VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced ...cancerres.aacrjournals.org/content/canres/73/2/539.full.pdf · VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory

The role of medical therapy in the management of desmoid tumor · Sunitinib: KIT, PDGFR , VEGFR and RET Sorafenib: KIT, PDGFR, VEGFR, RET and RAF. Sorafenib Gounder M.M. et al, ASCO